

# LES ESSENTIELS



# **ACIDE MÉTATARTRIQUE V40**

# Prevents crystallisation of potassium bitartrate

#### **CHARACTERISTICS**

**ACIDE MÉTATARTRIQUE V40** prevents precipitation of tartrates. It acts as an inhibitor of potassium bitartrate crystallisation. It is made by esterification of tartaric acid through controlled heating under vacuum.

#### **OENOLOGICAL PROPERTIES**

Production under vacuum in small batches together with strict, systematic monitoring of its index guarantees:

- maximum effectiveness at all times,
- rapid, complete dissolving,
- colourless, odourless solutions,
- a uniform index with a value of approximately 39.

Antitartrate protection increases in line with the esterification index up to an optimum value of 38/40. An index in excess of 40 can cause lasting cloudiness.

Under normal storage conditions, treated wine is protected against tartrate precipitation throughout the winter.

ACIDE MÉTATARTRIQUE V40 should be used on protein-free wine.

# **DOSAGE**

The addition of metatartaric acid is permitted up to 10 g/hL (maximum authorised dose).

## **INSTRUCTIONS FOR USE**

Dissolve ACIDE MÉTATARTRIQUE V40 in cold wine (1 kg /10 L of wine).

Avoid metal containers and instruments.

**ACIDE MÉTATARTRIQUE V40** precipitates out with residual lysozyme. Ensure that none is present before treatment.

Add the preparation before filtration during a pump-over (at least 1/3 of the tank) with a metering pump or a DOSACOL.

# Precautions for use:

Product for oenological and specifically professional use.

Use in accordance with current regulations.

## **PACKAGING**

1 kg and 25 kg

#### **STORAGE**

Store unopened, sealed packaging away from light in a dry, odour-free environment. Once opened use rapidly.

The information provided above is based on our current state of knowledge. This information is non-binding and without guarantee, since the conditions of use are beyond our control. It does not release the user from complying with existing legislation and safety data. This document is the property of SOFRALAB and may not be modified without its agreement.

044/2024 - 1/1